^
    Back
    Association details:
    Biomarker:HR negative
    Cancer:HER2 Negative Breast Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    11/24/2021
    Excerpt:
    HR-Negative/HER2-Negative disease...For high-risk: Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)